A Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AG-181 in Subjects With Phenylketonuria
← catalyst calendarNCT07241234 · readout in 516 d
Sponsored by Agios Pharmaceuticals, Inc. (industry) · AGIO — their whole pipeline →.
Phase
Phase 1
Status
Recruiting
Study type
Interventional
Design
Non randomized · None · Treatment
Enrollment
20estimated
Sites
4
Countries
Poland, United States
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2026-04-17 | actual | When the study began enrolling |
| Primary completion | 2028-01-17 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2028-01-17 | estimated | The whole study's end, after follow-up |
| First posted | 2025-11-21 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-07-30 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Phenylketonuria
Intervention
- Drug: AG-181
Primary outcome
what the primary-completion date above is the date OFNumber of Subjects with Adverse Events (AEs) and Serious Adverse Events (SAEs) by Type, Severity, and Relationship to the Study Drug
measured Up to Day 42
Permalink · AGIO's whole pipeline · Catalyst calendar · Every registered study · What changed